Evaluation of Microvascular Permeability with Dynamic Contrast-Enhanced MRI for the Differentiation of Primary CNS Lymphoma and Glioblastoma: Radiologic-Pathologic Correlation

REFERENCES

1. 1.↵
   1. Stupp R,
   2. Mason WP,
   3. van den Bent MJ,
   4. et al

   . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Schlegel U

   . Primary CNS lymphoma. Ther Adv Neurol Disord 2009;2:93–104

   Abstract/FREE Full Text
3. 3.↵
   1. Tofts PS

   . T1-weighted DCE imaging concepts: modelling, acquisition and analysis. MAGNETOM Flash 2010;30–39
4. 4.↵
   1. Nguyen TB,
   2. Cron GO,
   3. Mercier JF,
   4. et al

   . Diagnostic accuracy of dynamic contrast-enhanced MR imaging using a phase-derived vascular input function in the preoperative grading of gliomas. AJNR Am J Neuroradiol 2012;33:1539–45

   Abstract/FREE Full Text
5. 5.↵
   1. Cha S,
   2. Yang L,
   3. Johnson G,
   4. et al

   . Comparison of microvascular permeability measurements, K^trans, determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. AJNR Am J Neuroradiol 2006;27:409–17

   Abstract/FREE Full Text
6. 6.↵
   1. Mills SJ,
   2. Patankar TA,
   3. Haroon HA,
   4. et al

   . Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 2006;27:853–58

   Abstract/FREE Full Text
7. 7.↵
   1. Sorensen AG,
   2. Batchelor TT,
   3. Zhang WT,
   4. et al

   . A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009;69:5296–300

   Abstract/FREE Full Text
8. 8.↵
   1. Zhang W,
   2. Kreisl T,
   3. Solomon J,
   4. et al

   . Acute effects of bevacizumab on glioblastoma vascularity assessed with DCE-MRI and relation to patient survival. In: Proceedings of the 17th Scientific Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine, Honolulu, Hawaii; April 18–24, 2009:282
9. 9.↵
   1. Tofts PS,
   2. Kermode AG

   . Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991;17:357–67

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Cha S

    . Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 2006;27:475–87

    FREE Full Text
11. 11.↵
    1. Molnár PP,
    2. O'Neill BP,
    3. Scheithauer BW,
    4. et al

    . The blood-brain barrier in primary CNS lymphomas: ultrastructural evidence of endothelial cell death. Neuro Oncol 1999;1:89–100

    Abstract/FREE Full Text
12. 12.↵
    1. Schramm P,
    2. Xyda A,
    3. Klotz E,
    4. et al

    . Dynamic CT perfusion imaging of intra-axial brain tumours: differentiation of high-grade gliomas from primary CNS lymphomas. Eur Radiol 2010;20:2482–90

    CrossRefPubMed
13. 13.↵
    1. Warnke PC,
    2. Timmer J,
    3. Ostertag CB,
    4. et al

    . Capillary physiology and drug delivery in central nervous system lymphomas. Ann Neurol 2005;57:136–39

    CrossRefPubMed
14. 14.↵
    1. Toh CH,
    2. Wei KC,
    3. Chang CN,
    4. et al

    . Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction. AJNR Am J Neuroradiol 2013;34:1145–49

    Abstract/FREE Full Text
15. 15.↵
    1. Orton MR,
    2. d'Arcy JA,
    3. Walker-Samuel S,
    4. et al

    . Computationally efficient vascular input function models for quantitative kinetic modelling using DCE-MRI. Phys Med Biol 2008;53:1225–39

    CrossRefPubMed
16. 16.↵
    1. Louis DN,
    2. Ohgaki H,
    3. Wiestler OD,
    4. et al

    . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Patlak CS,
    2. Blasberg RG,
    3. Fenstermacher JD

    . Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1–7

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Bagher-Ebadian H,
    2. Jain R,
    3. Nejad-Davarani SP,
    4. et al

    . Model selection for DCE-T1 studies in glioblastoma. Magn Reson Med 2012;68:241–51

    CrossRefPubMed
19. 19.↵
    1. Bergamino M,
    2. Saitta L,
    3. Barletta L,
    4. et al

    . Measurement of blood-brain barrier permeability with T1-weighted dynamic contrast-enhanced MRI in brain tumors: a comparative study with two different algorithms. ISRN Neurosci 2013;2013:6
20. 20.↵
    1. Jain R,
    2. Bagher-Ebadian H,
    3. Narang J,
    4. et al

    . Optimal period of linearity using Patlak analysis in brain tumors. In: Proceedings of the 18th Scientific Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine, Stockholm, Sweden; May 1–7, 2010:4090
21. 21.↵
    1. Boxerman J,
    2. Schmainda K,
    3. Weisskoff R

    . Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859–67

    Abstract/FREE Full Text
22. 22.↵
    1. Boxerman JL,
    2. Prah DE,
    3. Paulson ES,
    4. et al

    . The role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard. AJNR Am J Neuroradiol 2012;33:1081–87

    Abstract/FREE Full Text
23. 23.↵
    1. Weisskoff RM,
    2. Boxerman JL,
    3. Sorensen AG,
    4. et al

    . Simultaneous blood volume and permeability mapping using a single Gd-based contrast injection. In: Proceedings of the 2nd Scientific Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine, San Francisco, California; August 6–12, 1994
24. 24.↵
    1. Emblem K,
    2. Mouridsen K,
    3. Borra R,
    4. et al

    . Does DSC-derived CA extravasation correlate with DCE Ktrans? In: Proceedings of the 19th International Society of Magnetic Resonance in Medicine, Montreal, Quebec, Canada; May 6–13, 2011
25. 25.↵
    1. Emblem KE,
    2. Bjornerud A,
    3. Mouridsen K,
    4. et al

    . T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI. Part II. Predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients. J Cereb Blood Flow Metab 2011;31:2054–64

    CrossRefPubMed
26. 26.↵
    1. Bjornerud A,
    2. Sorensen AG,
    3. Mouridsen K,
    4. et al

    . T1- and T2*-dominant extravasation correction in DSC-MRI: part I–theoretical considerations and implications for assessment of tumor hemodynamic properties. J Cereb Blood Flow Metab 2011;31:2041–53

    CrossRefPubMed
27. 27.↵
    1. McDonald DM,
    2. Choyke PL

    . Imaging of angiogenesis: from microscope to clinic. Nat Med 2003;9:713–25

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Hartmann M,
    2. Heiland S,
    3. Harting I,
    4. et al

    . Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett 2003;338:119–22

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Wang S,
    2. Kim S,
    3. Chawla S,
    4. et al

    . Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2011;32:507–14

    Abstract/FREE Full Text
30. 30.↵
    1. Liao W,
    2. Liu Y,
    3. Wang X,
    4. et al

    . Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Acta Radiol 2009;50:217–25

    Abstract/FREE Full Text
31. 31.↵
    1. Wong ET,
    2. Brem S

    . Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Canc Netw 2008;6:515–22

    Abstract/FREE Full Text
32. 32.↵
    1. Lister A,
    2. Abrey LE,
    3. Sandlund JT

    . Central nervous system lymphoma. Hematology Am Soc Hematol Educ Program 2002:283–96
33. 33.↵
    1. Tonn JC,
    2. Westphal M,
    3. Rutka JT,
    4. et al.

    1. Schlegel U,
    2. Hochberg F

    . Primary CNS lymphoma. In: Tonn JC, Westphal M, Rutka JT, et al., eds. Neuro-Oncology of CNS Tumors. Heidelberg, Germany: Springer-Verlag; 2006:292–302